Padma Sundar is VP of Strategy and Market Access at CallMax Life,
a liquid biopsy company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. Sundar is responsible for corporate strategy, market access and marketing at CellMax Life. She has over 20 years of experience commercializing and driving adoption of novel diagnostics. Prior to CellMax, Sundar led product management and marketing for Guardant Health's liquid biopsy, leading to its adoption by 80% of oncologists in the United States. Sundar also led product management at Roche Sequencing for their liquid biopsy tests, which have been launched in over 50 countries worldwide for cancer treatment selection and monitoring. Sundar began her career at McKinsey & Company’s healthcare practice. She has an MBA-MPH from UC Berkeley and a Bachelors in Chemistry.
Onco’Zine, The International Oncology Network (ISSN 2168-5339) is published by Sunvalley Communication, LLC. The journal publishes a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. Onco’Zine is a sponsor-supported, interactive online community for healthcare professionals and other medical specialists involved in the management and care of cancer patients.